Clinical implications of genomic evaluations for prostate cancer risk stratification, screening, and treatment: a narrative review

Prostate International - Tập 8 - Trang 99-106 - 2020
Jae-Seung Chung1, Todd M. Morgan2, Sung Kyu Hong3,4
1Department of Urology, Inje University Haeundae Paik Hospital, Busan, Korea
2Department of Urology, University of Michigan, Rogel Cancer Center, Ann Arbor, MI, USA
3Department of Urology, Seoul National University College of Medicine, Seoul, Korea
4Department of Urology, Seoul National University Bundang Hospital, Seongnam-si, Korea

Tài liệu tham khảo

Siegel, 2020, Cancer statistics, 2020, CA Canc J Clin, 70, 7, 10.3322/caac.21590

Liss, 2015, Impact of family history on prostate cancer mortality in white men undergoing prostate specific antigen based screening, J Urol, 193, 75

Leongamornlert, 2014, Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease, Br J Canc, 110, 1663, 10.1038/bjc.2014.30

Zhen, 2018, Genetic testing for hereditary prostate cancer:Current status and limitations, Cancer, 124, 3105, 10.1002/cncr.31316

McGrath, 2016, Prostate cancer biomarkers: Are we hitting the mark?, Prostate Int, 4, 130, 10.1016/j.prnil.2016.07.002

2015, The molecular taxonomy of primary prostate cancer, Cell, 163, 1011, 10.1016/j.cell.2015.10.025

Grasso, 2012, The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer, Nature, 487, 239, 10.1038/nature11125

Robinson, 2015, Integrative clinical genomics of advanced prostate cancer, Cell, 161, 1215, 10.1016/j.cell.2015.05.001

Giri, 2018, Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017, J Clin Oncol, 36, 414, 10.1200/JCO.2017.74.1173

Das, 2019, Bringing Prostate Cancer Germline Genetics into Clinical Practice, J Urol, 202, 223

Loeb, 2014, Overdiagnosis and overtreatment of prostate cancer, Eur Urol, 65, 1046, 10.1016/j.eururo.2013.12.062

Na, 2017, Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death, Eur Urol, 71, 740, 10.1016/j.eururo.2016.11.033

Grindedal, 2009, Germ-line mutations in mismatch repair genes associated with prostate cancer, Canc Epidemiol Biomarkers prev, 18, 2460, 10.1158/1055-9965.EPI-09-0058

Ryan, 2014, Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis, Canc Epidemiol Biomarkers prev, 23, 437, 10.1158/1055-9965.EPI-13-1165

Leongamornlert, 2012, Germline BRCA1 mutations increase prostate cancer risk, Br J Canc, 106, 1697, 10.1038/bjc.2012.146

Thompson, 2002, Cancer incidence in BRCA1 mutation carriers, J Natl Cancer Inst, 94, 1358, 10.1093/jnci/94.18.1358

van Asperen, 2005, Cancer risks in BRCA2 families: estimates for sites other than breast and ovary, J Med Genet, 42, 711, 10.1136/jmg.2004.028829

Edwards, 2003, Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene, Am J Hum Genet, 72, 1, 10.1086/345310

Agalliu, 2007, Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer, Br J Canc, 97, 826, 10.1038/sj.bjc.6603929

Kote-Jarai, 2011, BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients, Br J Canc, 105, 1230, 10.1038/bjc.2011.383

Castro, 2013, Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer, J Clin Oncol, 31, 1748, 10.1200/JCO.2012.43.1882

Pritchard, 2016, Inherited DNA-repair gene mutations in men with metastatic prostate cancer, N Engl J Med, 375, 443, 10.1056/NEJMoa1603144

Ewing, 2012, Germline mutations in HOXB13 and prostate-cancer risk, N Engl J Med, 366, 141, 10.1056/NEJMoa1110000

MacInnis, 2013, Population-based estimate of prostate cancer risk for carriers of the HOXB13 missense mutation G84E, PloS One, 8, 10.1371/journal.pone.0054727

Karlsson, 2014, A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk, Eur Urol, 65, 169, 10.1016/j.eururo.2012.07.027

Naslund-Koch, 2016, Increased risk for other cancers in addition to breast cancer for CHEK2∗1100delC heterozygotes estimated from the Copenhagen General Population Study, J Clin Oncol, 34, 1208, 10.1200/JCO.2015.63.3594

Daly, 2017, NCCN Guidelines Insights: Genetic Familial High-Risk Assessment: Breast and Ovarian (Version 2.2017), J Natl Compr Canc Netw, 15, 9, 10.6004/jnccn.2017.0003

Carroll, 2016, NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016, J Natl Compr Canc Netw, 14, 509, 10.6004/jnccn.2016.0060

Nyberg, 2020, Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study, Eur Urol, 77, 24, 10.1016/j.eururo.2019.08.025

Bancroft, 2014, Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study, Eur Urol, 66, 489, 10.1016/j.eururo.2014.01.003

Page, 2019, Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers, Eur Urol, 76, 831, 10.1016/j.eururo.2019.08.019

Buyyounouski, 2012, Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer, J Clin Oncol, 30, 1857, 10.1200/JCO.2011.35.1924

Fraser, 2017, Genomic hallmarks of localized, non-indolent prostate cancer, Nature, 541, 359, 10.1038/nature20788

Gallagher, 2010, Germline BRCA mutations denote a clinicopathologic subset of prostate cancer, Clin Canc Res, 16, 2115, 10.1158/1078-0432.CCR-09-2871

Sanda, 2018, Clinically localized prostate cancer: AUA/ASTRO/SUO Guideline. Part I. Risk stratification, shared decision making, and care options, J Urol, 199, 683

Chen, 2016, Active surveillance for the management of localized prostate cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement, J Clin Oncol, 34, 2182, 10.1200/JCO.2015.65.7759

Yamamoto, 2016, Metastatic prostate cancer in men initially treated with active surveillance, J Urol, 195, 1409

Chun, 2008, Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men, Cancer, 113, 701, 10.1002/cncr.23610

Chung, 2011, Nomogram to predict insignificant prostate cancer at radical prostatectomy in Korean men: a multi-center study, Yonsei Med J, 52, 74, 10.3349/ymj.2011.52.1.74

Shukla-Dave, 2012, Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer, BJU Int, 109, 1315, 10.1111/j.1464-410X.2011.10612.x

Wu, 2020, Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer, Eur Urol Oncol, 3, 224, 10.1016/j.euo.2019.12.003

Carter, 2019, Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer, Eur Urol, 75, 743, 10.1016/j.eururo.2018.09.021

Castro, 2015, Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer, Eur Urol, 68, 186, 10.1016/j.eururo.2014.10.022

Mateo, 2017, DNA Repair in Prostate Cancer: Biology and Clinical Implications, Eur Urol, 71, 417, 10.1016/j.eururo.2016.08.037

Boström, 2015, Genomic Predictors of Outcome in Prostate Cancer, Eur Urol, 68, 1033, 10.1016/j.eururo.2015.04.008

Pettersson, 2012, The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis, Canc Epidemiol Biomarkers Prev, 21, 1497, 10.1158/1055-9965.EPI-12-0042

Karnes, 2010, The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status, Canc Res, 70, 8994, 10.1158/0008-5472.CAN-10-1358

Gasi Tandefelt, 2013, A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers, Eur Urol, 64, 941, 10.1016/j.eururo.2013.02.039

Leinonen, 2013, Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer, Canc Epidemiol Biomarkers Prev, 22, 2333, 10.1158/1055-9965.EPI-13-0333-T

Yoshimoto, 2008, Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome, Mod Pathol, 21, 1451, 10.1038/modpathol.2008.96

Cooperberg, 2013, Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort, J Clin Oncol, 31, 1428, 10.1200/JCO.2012.46.4396

Bishoff, 2014, Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy, J Urol, 192, 409

Erho, 2013, Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy, PloS One, 8, 10.1371/journal.pone.0066855

Ross, 2014, A genomic classifier predicting metastatic disease progression inmenwith biochemical recurrence after prostatectomy, Prostate Cancer Prostatic Dis, 17, 64, 10.1038/pcan.2013.49

Karnes, 2013, Validation of a genomic classifier that predictsmetastasis following radical prostatectomy in an at risk patient population, J Urol, 190, 2047

Den, 2014, Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy, Int J Radiat Oncol Biol Phys, 89, 1038, 10.1016/j.ijrobp.2014.04.052

Klein, 2014, A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling, Eur Urol, 66, 550, 10.1016/j.eururo.2014.05.004

Cullen, 2015, A biopsy-based 17-gene Genomic Prostate Score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer, Eur Urol, 68, 123, 10.1016/j.eururo.2014.11.030

Crawford, 2014, Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry, Curr Med Res Opin, 30, 1025, 10.1185/03007995.2014.899208

Lorente, 2015, Sequencing of agents in castration-resistant prostate cancer, Lancet Oncol, 16, e279, 10.1016/S1470-2045(15)70033-1

de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 364, 1995, 10.1056/NEJMoa1014618

Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 367, 1187, 10.1056/NEJMoa1207506

Antonarakis, 2014, AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer, N Engl J Med, 371, 1028, 10.1056/NEJMoa1315815

Scher, 2017, Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer, Eur Urol, 71, 874, 10.1016/j.eururo.2016.11.024

Bernemann, 2017, Expression of AR-V7 in circulating tumour cells does not preclude response to next generation androgen deprivation therapy in patients with castration resistant prostate cancer, Eur Urol, 71, 1, 10.1016/j.eururo.2016.07.021

Steinestel, 2017, Eur Urol, 72, e168, 10.1016/j.eururo.2017.06.031

Gillessen, 2018, Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017, Eur Urol, 73, 178, 10.1016/j.eururo.2017.06.002

De Laere, 2019, TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer, Clin Canc Res, 25, 1766, 10.1158/1078-0432.CCR-18-1943

Chung, 2019, Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer, Neoplasia, 21, 802, 10.1016/j.neo.2019.06.002

Isaacsson Velho, 2020, Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer, Eur Urol, 77, 14, 10.1016/j.eururo.2019.05.032

Annala, 2017, Treat-ment outcomes and tumor loss of heterozygosity in germline DNA repair-deficient prostate cancer, Eur Urol, 72, 34, 10.1016/j.eururo.2017.02.023

Antonarakis, 2018, Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide, Eur Urol, 74, 218, 10.1016/j.eururo.2018.01.035

Farmer, 2005, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, 434, 917, 10.1038/nature03445

Bryant, 2005, Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase, Nature, 434, 913, 10.1038/nature03443

Kaufman, 2015, Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation, J Clin Oncol, 33, 244, 10.1200/JCO.2014.56.2728

Mateo, 2015, DNA-repair defects and olaparib in metastatic prostate cancer, N Engl J Med, 373, 1697, 10.1056/NEJMoa1506859

Abida, 2020, Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study, Clin Canc Res, 26, 2487, 10.1158/1078-0432.CCR-20-0394

Marshall, 2019, Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations, Eur Urol, 76, 452, 10.1016/j.eururo.2019.02.002

Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733

Antonarakis, 2019, Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations, Eur Urol, 75, 378, 10.1016/j.eururo.2018.10.009

Eiber, 2017, Prostate-specific membrane antigen ligands for imaging and therapy, J Nucl Med, 58, 67s, 10.2967/jnumed.116.186767

Rahbar, 2016, Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis, J Nucl Med, 57, 1334, 10.2967/jnumed.116.173757

Ahmadzadehfar, 2017, Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [(177)Lu]Lu-PSMA-617, Eur J Nucl Med Mol Imag, 44, 1448, 10.1007/s00259-017-3716-2

Rahbar, 2017, German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients, J Nucl Med, 58, 85, 10.2967/jnumed.116.183194

Paschalis, 2019, Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer, Eur Urol, 76, 469, 10.1016/j.eururo.2019.06.030

Crumbaker, 2020, Exceptional response to 177Lutetium prostate-specific membrane antigen in prostate cancer harboring DNA repair defects, JCO Precis Oncol

Beltran, 2014, Aggressive variants of castration-resistant prostate cancer, Clin Canc Res, 20, 2846, 10.1158/1078-0432.CCR-13-3309

Tan, 2008, ‘‘BRCAness’’ syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2mutations, J Clin Oncol, 26, 5530, 10.1200/JCO.2008.16.1703

Cheng, 2016, Biallelic inactivation of BRCA2 in platinum-sensitive, metastatic castration-resistant prostate cancer, Eur Urol, 69, 992, 10.1016/j.eururo.2015.11.022

Pomerantz, 2017, The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer, Cancer, 123, 3532, 10.1002/cncr.30808

Zafeiriou, 2019, Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency, Eur Urol, 75, 184, 10.1016/j.eururo.2018.09.048

Parker, 2013, Alpha emitter radium-223 and survival in metastatic prostate cancer, N Engl J Med, 369, 213, 10.1056/NEJMoa1213755

Suominen, 2017, Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models, Clin Canc Res, 23, 4335, 10.1158/1078-0432.CCR-16-2955

Nilsson, 2005, First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases, Clin Canc Res, 11, 4451, 10.1158/1078-0432.CCR-04-2244

Isaacsson Velho, 2019, Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects, Eur Urol, 76, 170, 10.1016/j.eururo.2018.09.040

van der Doelen, 2020, Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer, Eur J Canc, 136, 16, 10.1016/j.ejca.2020.05.001

Thông tin
Thông tin xuất bản

Prostate International

Tập 8

99-106

Thông tin tác giả